Lifesciences@Work : We help scientists build their business

Silenti Solutions

The company’s first product consists of a lentiviral vector encoding a patented combination of specific short hairpin RNAs (shRNAs) that target the HIV genome and will be introduced into the patient’s stem cells.

The shRNAs block HIV replication in the immune cells that express them, preventing their destruction and thus stopping the onset of AIDS. In treatment-refractory HIV infected individuals, this might result in a treatment that would be their only life-saving option.